TY - JOUR
T1 - A joint ESTRO and AAPM guideline for development, clinical validation and reporting of artificial intelligence models in radiation therapy
AU - Hurkmans, Coen
AU - Bibault, Jean Emmanuel
AU - Brock, Kristy K.
AU - van Elmpt, Wouter
AU - Feng, Mary
AU - David Fuller, Clifton
AU - Jereczek-Fossa, Barbara A.
AU - Korreman, Stine
AU - Landry, Guillaume
AU - Madesta, Frederic
AU - Mayo, Chuck
AU - McWilliam, Alan
AU - Moura, Filipe
AU - Muren, Ludvig P.
AU - El Naqa, Issam
AU - Seuntjens, Jan
AU - Valentini, Vincenzo
AU - Velec, Michael
N1 - Funding Information:
We thank Marjan Sharabiani for her invaluable help in the conceptualization of this work, guidance through the Delphi process and fruitful scientific discussions. She was supported by a grant from the EORTC Cancer Research Fund. We acknowledge the comprehensive review of this guideline by the ESTRO and AAPM reviewers. We sincerely appreciate their valuable comments and suggestions, which helped improving the quality of the manuscript. Disclaimer, ESTRO cannot endorse all statements or opinions made on the guidelines. Regardless of the vast professional knowledge and scientific expertise in the field of radiation oncology that ESTRO possesses, the Society cannot inspect all information to determine the truthfulness, accuracy, reliability, completeness or relevancy thereof. Under no circumstances will ESTRO be held liable for any decision taken or acted upon as a result of reliance on the content of the guidelines. The component information of the guidelines is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the guidelines is done so for solely educational and scientific purposes. ESTRO and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the guidelines. This includes any implied warranties and conditions that may be derived from the aforementioned guidelines.
Publisher Copyright:
© 2024 The Authors
PY - 2024/8/1
Y1 - 2024/8/1
N2 - Background and purpose: Artificial Intelligence (AI) models in radiation therapy are being developed with increasing pace. Despite this, the radiation therapy community has not widely adopted these models in clinical practice. A cohesive guideline on how to develop, report and clinically validate AI algorithms might help bridge this gap. Methods and materials: A Delphi process with all co-authors was followed to determine which topics should be addressed in this comprehensive guideline. Separate sections of the guideline, including Statements, were written by subgroups of the authors and discussed with the whole group at several meetings. Statements were formulated and scored as highly recommended or recommended. Results: The following topics were found most relevant: Decision making, image analysis, volume segmentation, treatment planning, patient specific quality assurance of treatment delivery, adaptive treatment, outcome prediction, training, validation and testing of AI model parameters, model availability for others to verify, model quality assurance/updates and upgrades, ethics. Key references were given together with an outlook on current hurdles and possibilities to overcome these. 19 Statements were formulated. Conclusion: A cohesive guideline has been written which addresses main topics regarding AI in radiation therapy. It will help to guide development, as well as transparent and consistent reporting and validation of new AI tools and facilitate adoption.
AB - Background and purpose: Artificial Intelligence (AI) models in radiation therapy are being developed with increasing pace. Despite this, the radiation therapy community has not widely adopted these models in clinical practice. A cohesive guideline on how to develop, report and clinically validate AI algorithms might help bridge this gap. Methods and materials: A Delphi process with all co-authors was followed to determine which topics should be addressed in this comprehensive guideline. Separate sections of the guideline, including Statements, were written by subgroups of the authors and discussed with the whole group at several meetings. Statements were formulated and scored as highly recommended or recommended. Results: The following topics were found most relevant: Decision making, image analysis, volume segmentation, treatment planning, patient specific quality assurance of treatment delivery, adaptive treatment, outcome prediction, training, validation and testing of AI model parameters, model availability for others to verify, model quality assurance/updates and upgrades, ethics. Key references were given together with an outlook on current hurdles and possibilities to overcome these. 19 Statements were formulated. Conclusion: A cohesive guideline has been written which addresses main topics regarding AI in radiation therapy. It will help to guide development, as well as transparent and consistent reporting and validation of new AI tools and facilitate adoption.
KW - Artificial Intelligence
KW - Deep learning
KW - Ethics
KW - Guideline
KW - Machine Learning
KW - Quality Assurance
KW - Radiation Therapy
KW - Segmentation
KW - Treatment planning
U2 - 10.1016/j.radonc.2024.110345
DO - 10.1016/j.radonc.2024.110345
M3 - Article
SN - 0167-8140
VL - 197
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 110345
ER -